We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Finger Prick Test Could Transform Heart Attack Prevention

By LabMedica International staff writers
Posted on 14 Feb 2025
Print article
Image: The blood test paves the way for better heart attack prevention (Photo courtesy of 123RF)
Image: The blood test paves the way for better heart attack prevention (Photo courtesy of 123RF)

Currently, blood-thinning medications are prescribed only to patients who have already experienced a heart attack or stroke, as these drugs can lead to serious bleeding in some individuals. Due to the lack of a reliable method to predict who may benefit or be harmed by these medications, doctors have been unable to prescribe them preventively to high-risk patients. Now, a new study suggests that a simple scoring system could transform how doctors prevent heart attacks and strokes by identifying patients who are most likely to benefit from preventive treatment.

The innovative test, known as the TRIPLE Score, was developed by researchers at the University of Reading (Berkshire, UK). It measures specific proteins on blood platelets, along with the patient's age, to help doctors make better-informed decisions about prescribing blood-thinning medications like aspirin and clopidogrel. Although the test is not yet widely available, the goal is to eventually make it suitable for point-of-care use. It will be incorporated into patient studies to verify its potential to enhance care.

In their study, published in Circulation Research, the team demonstrated that the TRIPLE Score effectively identified patients whose blood was more prone to forming clots in laboratory tests. The findings also correlated with established risk scores used by doctors to estimate a patient’s likelihood of having a heart attack within the next 10 years. The test requires just a small blood sample and could be developed into a simple tool that healthcare providers, not just specialists, could use in practice.

“Our new test will help doctors make sure that patients receive the best treatment and keep their quality of life,” said Dr. Alexander Bye, lead author of the research at the University of Reading. “Next, we aim to make the test even easier to use by developing a finger prick test, so that it as simple as measuring blood glucose."

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fixed Speed Tube Rocker
GTR-FS
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.